We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

NervGen Pharma Corp (NGEN) NPV

Sell:1.86 CAD Buy:1.89 CAD Change: 0.09 CAD (5.03%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
Sell:1.86 CAD
Buy:1.89 CAD
Change: 0.09 CAD (5.03%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
Sell:1.86 CAD
Buy:1.89 CAD
Change: 0.09 CAD (5.03%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The Company has two wholly owned subsidiaries, including NervGen US Inc. and NervGen Australia Pty Ltd.

Contact details

Address:
2955 Virtual Way, Suite 480
VANCOUVER
V5M 4X6
Canada
Telephone:
+1 (778) 7311711
Website:
https://www.nervgen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NGEN
ISIN:
CA64082X2032
Market cap:
81.58 million CAD
Shares in issue:
47.12 million
Sector:
Pharmaceuticals
Exchange:
Canadian Venture Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • William Radvak
    Executive Chairman of the Board, Co-Founder
  • Paul Brennan
    President, Chief Executive Officer, Director
  • William Adams
    Chief Financial Officer, Company Secretary
  • Nana Collett
    Vice President - Program Management
  • Dan Mikol
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.